Medicinal Chemistry Research

, Volume 27, Issue 6, pp 1624–1633 | Cite as

Synthesis, antimicrobial activity, and molecular docking study of fluorine-substituted indole-based imidazolines

  • Humberto L. Mendoza-Figueroa
  • Maria Trinidad Serrano-Alva
  • Gerardo Aparicio-Ozores
  • Gelacio Martínez-Gudiño
  • Oscar R. Suárez-Castillo
  • Nadia A. Pérez-Rojas
  • Martha S. Morales-Ríos
Original Research


A series of 2- or 3-(4,5-dihydro-1H-imidazol-2-yl)-1H-indole derivatives were synthesized, characterized, and evaluated for their in vitro antibacterial and antifungal activities. Additionally, the synthesized compounds were docked into the II DNA gyrase B active site, and their predicted binding modes were inspected. Inhibitory activity were tested against two species of Gram-negative bacteria (Escherichia coli, Pseudomonas aeruginosa), two species of Gram-positive bacteria (Staphylococcus aureus, Listeria monocytogenes) and two fungi (Candida albicans, Aspergillus niger) using the broth microdilution method. The fluorine-substituted 2-(2-imidazolyl)indole 2b was found to be the most potent antibacterial compound against E. coli and S. aureus strains (MIC value 80 μg/mL). Compounds showed better activity against Gram-positive bacteria compared to Gram-negative bacteria. The docking results predicted that the imidazoline-indole hybrid moiety bind to the active site protein ATP-binding pocket from E. coli and S. aureus with good interaction energy scores. The significant loss of antibacterial activity for some imidazoline-indole analogs could be attributed to several nonoptimal enzyme interactions, including poor hydrogen bonds provided by Asp73 (E. coli gyrase numbering) or Asp81 (S. aureus gyrase numbering) and an associated water molecule.


Imidazole Indole Tautomers Antibacterial activity Docking studies Gyrase B 



The present work is partially supported by CONACYT grant 179187 and Programa de Fortalecimiento Académico del Posgrado de Alta Calidad.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

44_2018_2177_MOESM1_ESM.pdf (2.2 mb)
Supplementary Information


  1. Azam MA, Thathan J, Jubie S (2015) Dual targeting DNA gyrase B (GyrB) and topoisomerse IV (ParE) inhibitors: a review. Bioorg Chem 62:41–63CrossRefPubMedGoogle Scholar
  2. Bansal S, Kumar S, Aggarwal V, Joseph A (2014) Design, synthesis, docking study & antibacterial evaluation of 1,3-diarylpyrazolyl substituted indolin-2-ones. Indo Global J Pharm Sci 4:1–7Google Scholar
  3. Bisacchi GS, Manchester JI (2015) A new-class antibacterial-almost. Lessons in drug discovery and development: a critical analysis of more than 50 years of effort toward ATPase inhibitors of DNA gyrase and topoisomerase IV. ACS Infect Dis 1:4–41CrossRefPubMedGoogle Scholar
  4. Brvar M, Perdih A, Renko M, Anderluh G, Turk D, Solmajer T (2012) Structure-based discovery of substituted 4,5’-bithiazoles as novel DNA gyrase inhibitors. J Med Chem 55:6413–6426CrossRefPubMedGoogle Scholar
  5. Crouch RD (2009) Synthetic routes toward 2-substituted-2-imidazolines. Tetrahedron 65:2387–2397CrossRefGoogle Scholar
  6. Dash P, Kudav DP, Parihar JA (2004) Thioacetamide catalyzed transformation of nitriles to 2-substituted imidazolines. J Chem Res 7:490–491CrossRefGoogle Scholar
  7. Desroy N, Denis A, Oliveira C, Atamanyuk D, Briet S, Faivre F, LeFralliec G, Bonvin Y, Oxoby M, Escaich S, Floquet S, Drocourt E, Vongsouthi V, Durant L, Moreau F, Verhey TB, Lee T-W, Junop MS, Gerusz V (2013) Novel HldE-K inhibitors leading to attenuated gram negative bacterial virulence. J Med Chem 56:1418–1430CrossRefPubMedGoogle Scholar
  8. Fonquerna S, Miralpeix M, Pagès L, Puig C, Cardús A, Antón F, Cárdenas A, Vilella D, Aparici M, Calaf E, Prieto J, Gras J, Huerta JM, Warrellow G, Beleta J, Ryder H (2004) Synthesis and structure-activity relationships of novel Histamine H1 antagonists: Indolylpiperidinyl benzoic acid derivatives. J Med Chem 47:6326–6337CrossRefPubMedGoogle Scholar
  9. Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Scalmani G, Barone V, Mennucci B, Petersson GA, Nakatsuji H, Caricato M, Li X, Hratchian HP, Izmaylov AF, Bloino J, Zheng G, Sonnenberg JL, Hada M, Ehara M, Toyota K, Fukuda R, Hasegawa J, Ishida M, Nakajima T, Honda Y, Kitao O, Nakai H, Vreven T, Montgomery JA, Peralta JE, Ogliaro F, Bearpark M, Heyd JJ, Brothers E, Kudin KN, Staroverov VN, Kobayashi R, Normand J, Raghavachari K, Rendell A, Burant JC, Iyengar SS, Tomasi J, Cossi M, Rega N, Millam JM, Klene M, Knox JE, Cross JB, Bakken V, Adamo C, Jaramillo J, Gomperts R, Stratmann RE, Yazyev O, Austin AJ, Cammi R, Pomelli C, Ochterski JW, Martin RL, Morokuma K, Zakrzewski VG, Voth GA, Salvador P, Dannenberg JJ, Dapprich S, Daniels AD, Farkas Ö, Foresman JB, Ortiz JV, Cioslowski J, Fox DJ (2009) Gaussian 09. Gaussian, Inc., Wallingford CTGoogle Scholar
  10. Han L, Du DM (2009) Recent advances in the synthesis of 2-imidazolines and their applications in homogeneous catalysis. Adv Synth Catal 351:489–519CrossRefGoogle Scholar
  11. Joshi KC, Joshi R (2000) Fluorinated indole derivatives: synthetic and biomedicinal aspects. J Indian Chem Soc 77:627–634Google Scholar
  12. Koenig SG, Dankwardt JW, Liu Y, Zhao H, Singh SP (2010) A ligand-free, copper-catalyzed cascade sequence to indole-2-carboxylic esters. Tetrahedron Lett 51:6549–6551CrossRefGoogle Scholar
  13. Kou X, Zhao M, Qiao X, Zhu Y, Tong X, Shen Z (2013) Copper-catalyzed aromatic C-H bond cyanation by C-CN bond cleavage of inert acetonitrile. Chem Eur J 19:16880–16886CrossRefPubMedGoogle Scholar
  14. KumarMittal A, Singh D, Tripathi S (2011) Synthesis and antifungal activity of some new fluorinated 1-[2-hydroxyethyl]-3-ethoxycarbonyl-5-oxadiazolyl/triazolyl/pyrrolyl-aminocarbonylmethoxy-2-methylbenz[g]indoles. J Chem Bio Phy Sci 1:141–152Google Scholar
  15. Laskowski RA, Swindells MB (2011) LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model 51:2778–2786CrossRefPubMedGoogle Scholar
  16. Lee JH, Kim YG, Cho MH, Kim JA, Lee J (2012) 7-fluoroindole as an antivirulence compound against Pseudomonas aeruginosa. FEMS Microbiol Lett 329:36–44CrossRefPubMedGoogle Scholar
  17. Lei L, Hui-Zhu Y, Zhao-Hai Q, Xiao-Jing Y, Yu-Mei X, Nan L, Bin F (2011) Synthesis and fungicidal activity of thiazoline derivatives containing halogenated indolyl moiety. Phosphorus Sulfur Silicon Relat Elem 186:1790–1800CrossRefGoogle Scholar
  18. Lewis RJ, Singh OM, Smith CV, Skarzynski T, Maxwell A, Wonacott AJ, Wigley DB (1996) The nature of inhibition of DNA gyrase by the coumarins and the cyclothialidines revealed by X-ray crystallography EMBO J 15:1412–1420PubMedPubMedCentralGoogle Scholar
  19. Morales-Ríos MS, García-Vázquez B, Florán-Garduño B, Serrano-Alva MT (2015) Preparation of serotonin reuptake inhibitor for treating central nervous system disorders. Mex Pat Appl MX 2014011573 A 20150310.Google Scholar
  20. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ (2009) Autodock4 and AutoDockTools4: automated docking with selective receptor flexiblity. J Comput Chem 16:2785–2791CrossRefGoogle Scholar
  21. NCCLS (2003) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, M7-A6. National Committee for Clinical Laboratory Standards, Wayne, PAGoogle Scholar
  22. Nishiyama T, Hatae N, Yoshimura T, Takaki S, Abe T, Ishikura M, Hibino S, Choshi T (2016) 1c Concise synthesis of carbazole-1,4-quinones and evaluation of their antiproliferative activity against HCT-116 and HL-60 cells. Eu J Med Chem 121:561–577CrossRefGoogle Scholar
  23. Oblak M, Grdadolnik SG, Kotnik M, Jerala R, Filipic M, Solmajer T (2005) In silico fragment-based discovery of indolin-2-one analogues as potent DNA gyrase inhibitors. Bioorg Med Chem Lett 15:5207–5210CrossRefPubMedGoogle Scholar
  24. Oblak M, Miha M, Solmajer T (2007) Discovery and development of ATPase inhibitors of DNA gyrase as antibacterial agents. Curr Med Chem 14:2033–2047CrossRefPubMedGoogle Scholar
  25. Panchal RG, Ulrich RL, Lane D, Butler MM, Houseweart C, Opperman T, Williams JD, Peet NP, Moir DT, Nguyen T, Gussio R, Bowlin T, Bavari S (2009) Novel broad-spectrum Bis-(imidazolinylindole) derivatives with potent antibacterial activities against antibiotic-resistant strains. Antimicrob Agents Chemother 53:4283–4291CrossRefPubMedPubMedCentralGoogle Scholar
  26. Pérez-Alvarez V, Morales-Ríos MS, Hong E, Joseph-Nathan P (1997) Synthesis of 3-amino-2-(3-indolyl)propanol and propanoate derivatives and preliminary cardiovascular evaluation in rats. J Pharm Pharmacol 49:246–252CrossRefPubMedGoogle Scholar
  27. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE (2004) UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem 25:1605–1612CrossRefPubMedGoogle Scholar
  28. Rivera-Becerril E, Joseph-Nathan P, Pérez-Alvarez VM, Morales-Ríos MS (2008) Synthesis and biological evaluation of (-)- and (+)-debromoflustramine B and its analogues as selective butyrylcholinesterase inhibitors. J Med Chem 51:5271–5284CrossRefPubMedGoogle Scholar
  29. Sawa N (1968) Nippon Kagaku Zasshi 89:780. (1969) Chem Abstr 70:19983Google Scholar
  30. Servi S, Genc M, Gür G, Koca M (2005) The synthesis and antimicrobial activity of some new methyl N-arylthiocarbamates, dimethyl N-aryldithiocarbonimidates and 2-arylamino-2-imidazolines. Eu J Med Chem 40:687–693CrossRefGoogle Scholar
  31. Smart BE (2001) Fluorine substituent effects (on bioactivity). J Fluor Chem 109:3–11CrossRefGoogle Scholar
  32. Spadoni G, Diamantini G, Bedini A, Tarzia G, Vacondio F, Silva C, Rivara M, Mor M, Plazzi PV, Zusso M, Franceschini D, Giusti P (2006) Synthesis, antioxidant activity and structure–activity relationships for a new series of 2-(N-acylaminoethyl)indoles with melatonin-like cytoprotective activity. J Pineal Res 40:259–269CrossRefPubMedGoogle Scholar
  33. Spartan 14 (2013) Spartan’14 for Windows, macintosh, and linux. Wavefunction Inc., Irvine.
  34. Tejpal-Singh C, Poonam K, Nutan S, Sunita B (2016) Strategic synthesis and in vitro antimicrobial evaluation of novel difluoromethylated 1-(1, 3-diphenyl-1H-pyrazol-4-yl)-3, 3-difluoro-1, 3-dihydro-indol-2-ones. Med Chem Res 25:2335–2348CrossRefGoogle Scholar
  35. Trott O, Olson AJ (2010) Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31:455–461PubMedPubMedCentralGoogle Scholar
  36. WHO (World Health Organization) Antimicrobial resistance, Global Report on Surveillance (2014). Accessed 2 December 2016
  37. Wysong V, Whithe HC (1968) Substituted imidazolinyl índoles. US Patent 3,586,695.Google Scholar
  38. Zhang J, Yang Q, Cross JB, Romero JA, Poutsiaka KM, Epie F, Bevan D, Wang B, Zhang Y, Chavan A, Zhang X, Moy T, Daniel A, Nguyen K, Chamberlain B, Carter N, Shotwell J, Silverman J, Metcalf CA, Ryan D, Lippa B, Dolle RE (2015) Discovery of azaindole ureas as a novel class of bacterial Gyrase B inhibitors. J Med Chem 58:8503–8512CrossRefPubMedGoogle Scholar
  39. Zhou Y, Wang J, Gu Z, Wang S, Zhu W, Aceña JL, Soloshonok VA, Izawa K, Liu H (2016) Next generation of fluorine-containing pharmaceuticals, compounds currently in phase II−III clinical trials of major pharmaceutical companies: new structural trends and therapeutic areas. Chem Rev 116:422–518CrossRefPubMedGoogle Scholar
  40. Zidar N, Macut H, Tomašič T, Brvar M, Montalvão S, Tammela P, Solmajer T, Peterlin Mašič L, Ilaš J, Kikelj D (2015) N-phenyl-4,5-dibromopyrrolamides and N-phenylindolamides as ATP competitive DNA gyrase B inhibitors: design, synthesis, and evaluation. J Med Chem 58:6179–6194CrossRefPubMedGoogle Scholar
  41. Zoidis G, Giannakopoulou, Stevaert A, Frakolaki E, Myrianthopoulos V, Fytas G, Mavromara P, Mikros E, Bartenschlager R, Vassilaki N, Naesens L (2016) Novel indole–flutimide heterocycles with activity against influenza PA endonuclease and hepatitis C virus. Med Chem Comm 7:447–456CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Humberto L. Mendoza-Figueroa
    • 1
    • 2
  • Maria Trinidad Serrano-Alva
    • 1
    • 2
  • Gerardo Aparicio-Ozores
    • 3
  • Gelacio Martínez-Gudiño
    • 1
    • 2
  • Oscar R. Suárez-Castillo
    • 4
  • Nadia A. Pérez-Rojas
    • 1
  • Martha S. Morales-Ríos
    • 1
    • 2
  1. 1.Departamento de QuímicaCentro de Investigación y de Estudios Avanzados del Instituto Politécnico NacionalMexico CityMexico
  2. 2.Programa de Posgrado en FarmacologíaCentro de Investigación y de Estudios Avanzados del Instituto Politécnico NacionalMexico CityMexico
  3. 3.Departamento de Microbiología, Escuela Nacional de Ciencias BiológicasInstituto Politécnico NacionalMexico CityMexico
  4. 4.Área Académica de QuímicaUniversidad Autónoma del Estado de HidalgoHidalgoMexico

Personalised recommendations